Skip to main content
OpenTrials
Completed

NCT Number: NCT01505530

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Unresectable or metastatic pancreas cancer; participants with previous radical surgery for pancreas cancer are eligible after progression is documented
  • Participants may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreas cancer
  • ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2
  • Adequate organ function
  • Have an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment
  • Ability to perform the indicated functional performance measures at baseline

Exclusion:

  • Prior systemic therapy for unresectable/metastatic pancreas cancer
  • Any medical or psychiatric condition, orthopedic or neuromuscular conditions that could limit participation or confound study results
  • Currently taking medications that are considered both muscle building and performance enhancing (for example, androgen therapies, or anabolic steroids)

Treatment and study plan

LY2495655

Drug

Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.

Placebo

Drug

Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.

Standard of Care Chemotherapy

Drug

Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Baseline to Death from Any Cause (Up to 23 months)

    Overall survival (OS) duration was measured from the date of randomization to the date of death from any cause.

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: Baseline to Disease Progression or Death from Any Cause (Up to 16 months)

    PFS was defined as the time from date of first dose to the first observation of disease progression or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

  2. Percentage of Participants With Tumor Response Rate (RR)

    Time frame: Baseline to Disease Progression (Up to 11 months)

    Response rate (RR) was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.

  3. Duration of Response

    Time frame: First CR or PR to Disease Progression (Up to 11 months)

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR) was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 millimeters (mm). Partial Response (PR) was defined as having at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.

  4. Change in Lean Body Mass

    Time frame: Baseline, Cycles 3, 5, 7, 9 and 11; Day 1

    Change in lean body mass was assessed using dual-energy x-ray absorptiometry (DXA).

  5. Change in Physical Performance Measures Using Hand Grip Strength

    Time frame: Baseline, Cycles 2, 4, 6, 8 and 10; Day 1

    Hand grip strength (HGS) of the non-dominant hand measured using a hand dynamometer.

  6. Change in Physical Performance Measures Using the Time Up and Go (TUG) Test

    Time frame: Baseline, Cycles 2, 4, 6, 8 and 10; Day 1

    Time Up and Go (TUG) is a timed walking test designed to measure gait performance and balance. It measures in seconds the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm [18in], arm height 65 cm [25.6 in]), walk a distance of 3 meters (118 inches, approximately 10 feet), turn, walk back to the chair, and sit down.

  7. Change in Physical Performance Measures Using the 6 Minute Walk Test

    Time frame: Baseline, Cycles 2, 4, 6, 8 and 10; Day 1

    The 6 minute walk test measured the distance walked in 6 minutes, as quickly as possible, without running.

  8. Change in Physical Performance Measures Using Stair Climbing Time (StC)

    Time frame: Baseline, Cycles 3, 5, 7, 9 and 11; Day 1

    Stair climbing time (StC) measured the ascend and descend of a flight of 12 steps (each step 18 cm high and 28 cm deep).

  9. Change in Patient Reported Outcomes (PRO)

    Time frame: Baseline, Cycles 2, 4, 6, 8 and 10; Day 1

    Data from PRO scales are not be presented. An error in coding the scales (coded differently early and late in the study) occurred. Unable to determine which results were affected therefore analysis not completed.

  10. Change in Pain Scale Physical Functioning

    Time frame: Baseline, Cycles 2, 4, 6, 8 and 10; Day 1

    The 36-item Short-Form Health Survey (SF-36) pain scale is a generic, health-related scale assessing participant's quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health and 2 summary scores (mental component summary [MCS] and physical component summary [PCS]). The PCS physical functioning domain score ranges from 0 to 100 (higher scores indicate better health status).

  11. Number of Participants With Anti-LY2495655 Antibodies

    Time frame: Cycle 1, Day 1 and Day 29 (Pre-Dose); Cycle 6 Day 1

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy

Important dates

Study start
2011
Primary completion
2014
Study completion
2016
First posted
Jan 6, 2012
Registry last updated
Sep 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.